TITLE

Efficacy of pneumococcal vaccination in adults: a meta-analysis

AUTHOR(S)
Huss, Anke; Scott, Pippa; Stuck, Andreas E.; Trotter, Caroline; Egger, Matthias
PUB. DATE
January 2009
SOURCE
CMAJ: Canadian Medical Association Journal;1/6/2009, Vol. 180 Issue 1, p48
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine's efficacy on clinical outcomes as well as the methodologic quality of the trials. Methods: We searched several databases and all bibliographies of reviews and meta-analyses for clinical trials that compared pneumococcal polysaccharide vaccine with a control. We examined rates of pneumonia and death, taking the methodologic quality of the trials into consideration. Results: We included 22 trials involving 101 507 participants: 11 trials reported on presumptive pneumococcal pneumonia, 19 on all-cause pneumonia and 12 on allcause mortality. The current 23-valent vaccine was used in 8 trials. The relative risk (RR) was 0.64 (95% confidence interval [CI] 0.43-0.96) for presumptive pneumococcal pneumonia and 0.73 (95% CI 0.56-0.94) for all-cause pneumonia. There was significant heterogeneity between the trials reporting on presumptive pneumonia (I2 = 74%, p < 0.001) and between those reporting on all-cause pneumonia (I2 = 90%, p < 0.001). The RR for all-cause mortality was 0.97 (95% CI 0.87-1.09), with moderate heterogeneity between trials (... = 44%, p = 0.053). Trial quality, especially regarding double blinding, explained a substantial proportion of the heterogeneity in the trials reporting on presumptive pneumonia and all-cause pneumonia. There was little evidence of vaccine protection in trials of higher methodologic quality (RR 1.20, 95% CI 0.75-1.92, for presumptive pneumonia; and 1.19, 95% CI 0.95-1.49, for all-cause pneumonia in double-blind trials; p for heterogeneity > 0.05). The results for all-cause mortality in double-blind trials were similar to those in all trials combined. There was little evidence of vaccine protection among elderly patients or adults with chronic illness in analyses of all trials (RR 1.04, 95% CI 0.78-1.38, for presumptive pneumococcal pneumonia; 0.89, 95% CI 0.69- 1.14, for all-cause pneumonia; and 1.00, 95% CI 0.87-1.14, for all-cause mortality). Interpretation: Pneumococcal vaccination does not appear to be effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended.
ACCESSION #
35826033

 

Related Articles

  • The controversy over the efficacy of pneumococcal vaccine. Andrews, Ross; Moberley, Sarah A. // CMAJ: Canadian Medical Association Journal;1/6/2009, Vol. 180 Issue 1, p18 

    The author reflects on the meta-analysis of Huss and colleagues regarding the efficacy of pneumococcal polysaccharide vaccine in adults. The author compares the present study with the Cochrane review by citing the excluded several related studies. The author argues that the exclusion of lung...

  • Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older. Quach, C.; Baclic, O. // Canada Communicable Disease Report;Dec2016, Vol. 42 Issue 12, p260 

    Background: Since 2015, pneumococcal 13-valent conjugate vaccine (PNEU-C-13) has been authorized for the prevention of invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP) in adults. Adults with immunocompromising conditions are still recommended to receive...

  • Immune Response to Pneumococcal Conjugate and Polysaccharide Vaccines in Otitis-Prone and Otitis-Free Children. Barnett, Elizabeth D.; Pelton, Stephen I.; Cabral, Howard J.; Eavey, Roland D.; Allen, Carole; Cunningham, Michael J.; McNamara, Eileen R.; Klein, Jerome O. // Clinical Infectious Diseases;7/1/99, Vol. 29 Issue 1, p191 

    Provides information on a study which compared responses to the pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine to understand the roles of vaccines in the prevention of pneumococcal disease including otitis media. How the study was conducted; Results; Discussion of...

  • Protecting against invasive pneumococcal disease: Be wise--immunize! Squires, Susan G.; Spika, John S. // CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p826 

    Discusses invasive pneumococcal pneumonia. Characteristics; Treatment choices; Recommendations from the Canadian Immunization Guide; Introduction of pneumococcal vaccination programs for high-risk groups in Canada.

  • Pneumovax II.  // Royal Society of Medicine: Medicines;2002, p443 

    The article presents information on Pneumovax II which is a proprietary, prescription-only vaccine preparation of pneumococcal vaccine in the form polyvalent unconjugated pneumococcal polysaccharide vaccine. It can be used for the prevention of pneumococcal pneumonia in people over two years for...

  • Pnu-Imune.  // Royal Society of Medicine: Medicines;2002, p443 

    The article presents information on Pnu-Imune which is a proprietary, prescription-only vaccine preparation of pneumococcal vaccine in the form polyvalent unconjugated pneumococcal polysaccharide vaccine. It can be used for the prevention of pneumococcal pneumonia in people over two years for...

  • pneumococcal vaccine.  // Royal Society of Medicine: Medicines;2002, p443 

    The article presents information on pneumococcal vaccine which is used for immunization against pneumonia. There are two types of vaccine. First is the polyvalent unconjugated pneumococcal polysaccharide vaccine and second is the polyvalent pneumococcal polysaccharide conjugated vaccine....

  • Adult immunization rates significantly lacking. Shafer, Emily // Infectious Disease News;Oct2012, Vol. 25 Issue 10, p1 

    The article reports that coverage rate for pneumococcal vaccine among adults aged 19 to 64 years in the U.S. remains low as of October 2012.

  • Erratum to: Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Torres, A.; Bonanni, P.; Hryniewicz, W.; Moutschen, M.; Reinert, R.; Welte, T. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2015, Vol. 34 Issue 2, p415 

    A correction to the article "Pneumococcal Vaccination: What Have We Learnt So Far and What Can We Expect in the Future?" that was published in the October 2014 issue is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics